Researchers are uncovering promising links between GLP-1 receptor agonists and reduced risks of obesity-related cancers, potentially revolutionizing treatment approaches. Recent studies, including one from Case Western, reveal that both bariatric surgery and GLP-1 drugs significantly decrease the risk of such cancers. The findings suggest that GLP-1 users have notably lower cancer risks compared to those using insulin or metformin. This discovery fuels optimism for the future, with retrospective studies planned for 2025 expected to provide more detailed insights into GLP-1's effects on cancer risks.
The research has shown that individuals using GLP-1 drugs experience a 50% reduction in cancer risk compared to insulin users, and a 42% reduction compared to metformin users. Furthermore, these drugs appear to mitigate fatty liver disease, potentially slowing the progression to liver cancer. A study published in December 2023 highlighted that people with type 2 diabetes taking GLP-1s had a 44% lower risk for colorectal cancer than those on insulin, and a 25% lower risk than those on metformin.
In a comprehensive U.S. study involving over 1.6 million patients with type 2 diabetes, researchers observed significant reductions in the risk of 10 out of 13 obesity-associated cancers for those using GLP-1 drugs. However, there was a slight increase in kidney cancer risk compared to metformin users. Notably, those who underwent bariatric surgery saw a 22% risk reduction over ten years, while GLP-1 users experienced a 39% reduction.
Despite these positive findings, some researchers express concerns about potential associations between GLP-1s and increased cancer risks. However, a systematic review and meta-analysis of semaglutide and cancer risks found no increased risks for any cancer type, including pancreatic and thyroid cancers. Additionally, Brazilian researchers found no increased risk for breast cancer or benign breast neoplasms associated with GLP-1s.
GLP-1 drugs have demonstrated improvements across multiple organ systems, enhancing cardiovascular, gastric, hepatic, and renal values. The latest GLP-1 receptor agonists are celebrated for their potential to boost weight loss and improve glucose control. Lindsey Wang, an expert in the field, explains that the protective effects against obesity-associated cancers likely arise from multiple mechanisms.
“The protective effects of GLP-1s against obesity-associated cancers likely stem from multiple mechanisms,” – Lindsey Wang
Wang further elaborates on how these drugs enhance insulin sensitivity and lower insulin levels, thereby decreasing cancer cell growth signals.
“They also enhance insulin sensitivity and lower insulin levels, decreasing cancer cell growth signals.” – Lindsey Wang
The long-term effects of GLP-1 drugs on cancer risks require extensive follow-up studies involving large patient populations, according to Wang.
“Usually, many years of follow-up of large numbers of patients are needed to see cancer effects of a carcinogen or cancer-preventing intervention.” – Lindsey Wang
Sonali Thosani emphasizes the importance of lifestyle changes in conjunction with these medications to achieve lasting reductions in cancer risks.
“If taking these drugs for a limited amount of time can help people lose weight and get on an exercise plan, then that’s helping lower cancer risk long-term,” – Sonali Thosani
She highlights that sustained lifestyle changes are crucial even after discontinuing the drugs.
“But it all comes back to someone making lifestyle changes and sticking to them, even after they stop taking the drugs,” – Sonali Thosani
Thosani believes that maintaining these changes could result in net positive outcomes for long-term cancer and health risks.
“If they can do that, then you’ll probably see a net positive for long-term cancer risks and other long-term health risks.” – Sonali Thosani
Anne McTiernan sees a transformative potential for GLP-1 drugs in addressing obesity and its associated cancer burden if accessibility can be ensured.
“I foresee that this class of drugs will revolutionize obesity and the cancer burden that comes with it, if people can get access,” – Anne McTiernan
Leave a Reply